Stem Cell Therapeutics Corp. Announces Presentation at 2nd Annual HOPE Conference for Parkinson's
May 22 2009 - 8:32AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) (the "Company" or
"SCT") is pleased to announce that Dr. Allen Davidoff, VP Product
Development, will be the featured speaker this evening at the 2nd
Annual HOPE Conference for Parkinson's. The Conference is hosted by
the Parkinson's Society of Southern Alberta and will take place at
the Carriage House Inn, May 22-23 in Calgary, Alberta.
Dr. Davidoff will be discussing the possibility of drug-based
therapies to regenerate brain tissue and improve outcomes for
individuals who have experienced losses due to central nervous
system diseases, such as Parkinson's disease.
Dr. Allen Davidoff commented that "even though Parkinson's
disease is not one of our three focus areas of stroke, traumatic
brain injury and multiple sclerosis, it still represents an
important application for our technology and intellectual property,
and is one that we would like to develop with a collaborative
partner."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair neurological function lost due to disease or injury. SCT's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem
Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
(403) 245-5495 ext.221 Email: crampton@stemcellthera.com Website:
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024